, Volume 74, Issue 12, pp 1371–1378 | Cite as

Tafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy

  • Lesley J. ScottEmail author
Adis Drug Evaluation


Oral tafamidis (Vyndaqel®) is indicated in the EU for the treatment of transthyretin (TTR) amyloidosis in adult patients with early stage symptomatic polyneuropathy to delay peripheral neurologic impairment and, in Argentina, Japan and Mexico, for delaying the peripheral neurological impairment of TTR familial amyloid polyneuropathy (TTR-FAP). It is the first disease-modifying pharmacotherapy to be approved for use in adult patients with early-stage TTR-FAP. The drug acts to kinetically stabilize the variant TTR tetramer and thereby prevent tetramer dissociation, the rate-limiting step in TTR misfolding and amyloidogenesis. In the 18-month Fx-005 study in adult patients with early-stage V30M TTR-FAP, there were no statistically significant differences between tafamidis and placebo recipients for the coprimary endpoints, the Neuropathy Impairment Score-Lower Limb (NIS-LL) response rate (increase in NIS-LL score of <2) and the least-square mean change in Norfolk Quality-of-Life (QOL) Diabetic-Neuropathy Questionnaire total scores at 18 months, based on modified intent-to-treat analyses. However, in prespecified per-protocol analyses of efficacy evaluable patients, tafamidis recipients experienced significantly better outcomes in terms of these coprimary endpoints, with most (98 %) tafamidis recipients showing stabilization of TTR tetramers at study end. Secondary endpoint outcomes also favoured tafamidis treatment over placebo. The beneficial effects of tafamidis in slowing deterioration of neurological function and health-related-QOL were maintained in long-term extension studies (up to 66 months). Tafamidis also stabilized TTR tetramers in patients with non-V30M TTR-FAP. Tafamidis was generally well tolerated, with most treatment-emergent adverse events being of mild to moderate intensity and very few patients discontinuing treatment because of these events. No new safety signals have emerged during long-term extension studies and post-marketing experience.


V30M Mutation Familial Amyloid Polyneuropathy Coprimary Endpoint Neuropathy Impairment Score Tafamidis Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Lesley Scott is a salaried employee of Adis/Springer.


  1. 1.
    Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Hou X, Aguilar M-I, Small DH. Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086–97.PubMedCrossRefGoogle Scholar
  4. 4.
    Adams D, Théaudin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014;14(3):435.PubMedCrossRefGoogle Scholar
  5. 5.
    Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011–20.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Nencetti S, Rossello A, Orlandini E, et al. Tafamidis (Vyndaquel): a light for FAP patients. ChemMedChem. 2014;8(10):1617–9.Google Scholar
  7. 7.
    Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. Clin Pharm Ther. 2014;39(3):225–33.CrossRefGoogle Scholar
  8. 8.
    Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA. 2013;110(24):9992–7.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    European Medicines Agency. Vyndaqel (tafamidis) 20 mg soft capsules: summary of product characteristics. 2013. Accessed 5 May 2014.
  11. 11.
    Coelho T, Maia LF, da Martins Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Coelho T, Maia LF, da Martins Silva A, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260(11):2802–14.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Coelho T, Silva A, Maia L, et al. Long-term use of tafamidis in transthyretin familial amyloid polyneuropathy: a single center experience [abstract No. S58.005]. Neurology. 2013;80(1 Meeting Abstracts).Google Scholar
  14. 14.
    Coelho T, Conceição IM, Barroso F, et al. Long term effects of tafamidis treatment on transthyretin familial amyloid polyneuropathy (TTR-FAP): interim results of the Fx1A-303 study [abstract OS3114]. Eur J Neurol. 2014;21(Suppl 1):81.Google Scholar
  15. 15.
    Coelho T, Silva AM, Valdrez K, et al. Familial amyloid polyneuropathy treatment with tafamidis: evaluation of one year treatment in Porto, Portugal [abstract No. OP-67]. XIVth international symposium on amyloidosis; Apr 27-May 1 2014; Indianapolis, IN.Google Scholar
  16. 16.
    Damy T, Judge DP, Dogan A, et al. Cardiac safety and tolerability, and effects on cardiac function, of tafamidis in patients with non-V30M TTR-FAP [abstract No. P888]. Eur J Heart Failure. 2012;11(Suppl):S153–4.Google Scholar
  17. 17.
    Pfizer Inc. Familial amyloidosis support meeting. 2013. Accessed 5 May 2014.
  18. 18.
    Pfizer Inc. FDA issues complete response letter for Pfizer’s tafamidis meglumine new drug application. 2012. Accessed 5 May 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations